The poster reported on an open-label trial run by the Royal Free London NHS Foundation Trust at two sites in the UK and Ireland and which included data from 21 patients, five of whom were followed for twelve months. It concluded that nVNS, as delivered by electroCore's hand-held, home-use gammaCore device, appeared to be effective, safe and well-tolerated and useful for both acute and preventive treatment strategies of cluster headaches.
It further found that nVNS should be considered before surgically invasive neuro-stimulation, while the authors concluded that the data strongly supported the need for additional randomised studies of nVNS.